1.260USD+0.80%Mkt Cap: 112.77M USDP/E: —Last update: 2026-05-22
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central n…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap112.77M USD
Enterprise Value75.52M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-23.49M USD
Revenue/Share—
Last Price1.260 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.52
PEG—
EV/EBITDA-1.76
EV/Revenue—
P/S—
P/B3.25
EPS (TTM)-0.23
EPS (Forward)-0.28
52W Range
0.222029% of range3.830
52W High3.830 USD
52W Low0.2220 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-68.53%
ROA-48.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.59M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-36.17M USD
Net Debt/EBITDA0.84
Balance Sheet
Debt/Equity0.02
Current Ratio—
Quick Ratio—
Book Value/Sh0.3850 USD
Cash/Share0.4120 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)3.500 USD
Target Range3.000 USD – 4.000 USD
# Analysts4
Ownership
Shares Out.89.50M
Float82.31M
Insiders2.25%
Institutions23.49%
Short Interest
Short Ratio5.7d
Short % Float9.68%
Short % Out.8.93%
Shares Short7.98M
Short (prev mo.)6.85M
Technical
SMA 501.093 (+15.2%)
SMA 2001.435 (-12.2%)
Beta1.81
S&P 52W Chg28.31%
Avg Vol (30d)1.02M
Avg Vol (10d)879.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—